Skip to main content

Table 3 Three-year relative survival (RS) expressed as percentages with 95% confidence interval (95%CI)

From: Prognostic consequences of implementing cancer patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in primary care

 

Before CPP

During CPP

After CPP

    

Total

Non-CPP referred

CPP referred

RS

(95%CI)

RS

(95%CI)

RS

(95%CI)

RS

(95%CI)

RS

(95%CI)

CRC

63.8

(57.0;69.9)

66.4

(62.9;69.7)

69.3

(64.8;73.3)

70.8

(65.2;75.7)

65.4

(57.6;72.1)

Lung

11.3

(8.00;15.4)

16.2

(13.7;18.9)

20.4

(15.6;25.7)

19.5

(13.6;26.2)

20.9

(15.5;26.9)

Melanoma

89.6

(81.5;94.3)

91.7

(87.4;94.5)

91.9

(86.1;95.4)

95.6

(87.0;98.5)

85.3

(74.2;91.8)

Head & neck

57.0

(41.5;69.8)

70.3

(61.6;77.4)

73.6

(64.1;81.0)

77.8

(66.8;85.6)

58.5

(39.2;73.6)

Upper GI

18.5

(13.5;24.2)

19.8

(16.5;23.3)

18.5

(14.5;22.9)

17.4

(12.9;22.5)

a

 

Gynaecological

58.3

(48.7;66.8)

70.7

(67.1;77.4)

75.2

(68.2;80.8)

72.8

(64.5;79.5)

84.4

(70.8;92.0)

Urinary system

47.7

(38.5;56.3)

59.9

(54.2;65.1)

61.7

(53.1;69.3)

59.2

(48.6;68.4)

a

 

Total

44.5

(41.5;47.5)

51.0

(49.4;52.6)

54.4

(52.2;56.5)

54.5

(51.8;57.1)

54.1

(50.3;57.8)

  1. RS estimates are calculated using the complete approach and standardised using ICSS weights. Underlying mortality was accounted for using life tables. aCould not be computed due to a low number of cases